Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) have received a consensus rating of “Buy” from the six brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $6.20.

RIGL has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Rigel Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 target price for the company in a research note on Tuesday, May 2nd. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Rigel Pharmaceuticals in a research note on Wednesday, May 3rd. Jefferies Group LLC restated a “buy” rating and issued a $5.00 price target on shares of Rigel Pharmaceuticals in a report on Wednesday, March 8th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $4.00 price target on shares of Rigel Pharmaceuticals in a report on Wednesday, March 8th.

Large investors have recently bought and sold shares of the company. FMR LLC boosted its stake in Rigel Pharmaceuticals by 23.6% in the first quarter. FMR LLC now owns 18,335,735 shares of the biotechnology company’s stock worth $60,691,000 after buying an additional 3,502,456 shares during the last quarter. Wellington Management Group LLP boosted its stake in Rigel Pharmaceuticals by 31.1% in the first quarter. Wellington Management Group LLP now owns 13,843,629 shares of the biotechnology company’s stock worth $45,823,000 after buying an additional 3,282,390 shares during the last quarter. Vanguard Group Inc. boosted its stake in Rigel Pharmaceuticals by 20.3% in the first quarter. Vanguard Group Inc. now owns 5,691,035 shares of the biotechnology company’s stock worth $18,837,000 after buying an additional 960,345 shares during the last quarter. Palo Alto Investors LLC boosted its stake in Rigel Pharmaceuticals by 1.9% in the first quarter. Palo Alto Investors LLC now owns 4,254,623 shares of the biotechnology company’s stock worth $14,083,000 after buying an additional 78,000 shares during the last quarter. Finally, MARSHALL WACE ASIA Ltd bought a new stake in Rigel Pharmaceuticals during the first quarter worth approximately $5,935,000. Institutional investors and hedge funds own 89.84% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Rigel Pharmaceuticals, Inc. (RIGL) Receives Consensus Recommendation of “Buy” from Brokerages” was published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/06/19/rigel-pharmaceuticals-inc-rigl-receives-consensus-recommendation-of-buy-from-brokerages.html.

Rigel Pharmaceuticals (NASDAQ:RIGL) last announced its earnings results on Tuesday, May 2nd. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.01. Rigel Pharmaceuticals had a negative return on equity of 96.24% and a negative net margin of 354.14%. The firm had revenue of $3.58 million for the quarter, compared to the consensus estimate of $4.30 million. During the same period in the prior year, the business earned ($0.19) EPS.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. The Company’s clinical programs include clinical studies of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor in a range of indications.

Receive News & Ratings for Rigel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.